Member Info for Prion25

For the most serious diseases where there is a great unmet need the FDA have a fast track process providing there drug is safe and effective (there are many examples ). IMO I think because DOX is already an approved drug we only need to optimise efficacy , dosage and demonstrate reduced toxicity of AVA6000 through P2 to convince FDA to trigger approval 'AS sounds very confident on the ground breaking data and yes P3 trials would provide transformational data using different more powerful war heads and drug combinations Very exciting prospects for share holders and benefits to cancer suffers AMHO gla

Why has William Black bought 4M cheap shares in our little pharma company ?He must know something , a quick buck or exciting potential drug development ? Hopefully not eventual privatisation like my other investments like REDX & ETX

Cj an PL narrative sound like the Kremlin’s anti West disinformation machine

Just watched the webinar AS presentation and responses to questions were outstanding GLA

Https://www.bbc.co.uk/news/health-68762171

Remember this from September 2022

Professor Chris Brightling, NIHR Senior Investigator, Department of Respiratory Sciences at the University of Leicester,said: "This promising Long COVID data is very welcome in an area of enormous clinical need. While it merits further investigation, it is exciting to see that SNG001 may have a positive effect in reducing some of the most recognised and problematic symptoms associated with Long COVID which afflicts millions of people and for which there are no current treatments."

It all appears encouraging from the abstract on the TME/plasma levels and safety .The reason why AS was pulled back on his over enthusiasm imo because there is still a lot of work to be done to optimise the DLT and provide the greatest benefit of the treatment . AVA 6000 has change the treatment characteristics is it more or less short or long dosage , improved efficacy over standard Dox . Further data required hence further clinical trials it is moving in the right direction for sure when that data is achieved AS can start shouting from the roof tops

Another Theranos another Elizabeth Holmes’s ? despicable another of my Aim shares mugged me off

China's President Xi Jinping makes the front of the Financial Times as he is pictured in Beijing meeting US business figures. The paper notes Beijing is seeking to revive investors' confidence in the country amid tensions with the US continuing to flare. The broadsheet leads with big takeovers more than doubling in the first quarter of this year "signalling a nascent recovery in mergers and acquisitions after a long drought".

Pleased with this morning's update especially the validation of more potent warheads than Dox against FAP rich tumours This ensures that AVA 6000 will be an agnostic platform for drugs which remain at great expense to Big Parma on the side lines because their high toxicity The continuation of optimisation of the dose has slowed things up but the the Pre/CISION platform must achieve clinical excellence

Exciting developments here in a niche market for unmet needs for neurological disorders and disease but it is seems long journey to commercialisation unless there is Big Pharma involvement to expedite urgent treatment for long suffering patients

Ceres Power, a developer of the SteelCell®, a world-leading, low-cost Solid Oxide Fuel Cell (SOFC) technology, has entered into a partnership with Nissan to further develop fuel cell technology for Electric Vehicle (EV) applications1.

Ceres Power and The Welding Institute (TWI) have been awarded a total of £8m UK government funding through the Advanced Propulsion Centre (APC) for this project2. The project involves the design, build, test, and demonstration of a compact, robust, UK-produced SOFC stack, deployed within a Nissan designed fuel cell module suitable for operation with a variety of high-efficiency fuel types (including biofuels)2.

This partnership builds on the successful Joint Development with Nissan over the past 2 years and sees Ceres Power accelerating the commercialisation of its SteelCell® fuel cell technology in automotive markets. Ceres Power has six strategic partners, including Cummins, Honda & Nissan.

This collaboration is a significant step towards the development of cleaner and more efficient energy solutions for the automotive industry.

Https://www.fleetnews.co.uk/news/manufacturer-news/2016/07/15/nissan-signs-deal-with-ceres-power-for-alternative-fuel-cell

Geological hydrogen cheap and plentiful if and when it happens will be of benefit to Ceres for mega electric power generation .Would it not ?

The reduction of Dox Cardio toxicity itself is a blessing childhood cancers .Any potential improvement of efficacy over standard Dox is a godsend .AVA6000 has great potential

@CTFSFO

Agree peptide drug conjugate PDC put AVACTA in competition with ground breaking Antibody Drug Conjugates ADC in cancer treatments Bring it on

This sentence from my post should say

The scale of the opportunity being presented is positively breath taking Cancer drug sales worldwide are already ......

Turner Pope excellent article posted courtesy of iantobach certainly gives a clear picture to why they are considering a P3

To fully grasp/broaden

the drug’s international opportunity, a follow-on Phase 3 study (full design yet to be disclosed) is presently

scheduled to commence in Q1 2026 and may well be conducted with a partner or partners.

Recognising the limit of its own capabilities and the opportunity for the Group’s technologies to satisfy such a

significant unmet need in a timely manner, out-licensing and partnership agreements with sector leaders (that

could possibly include the likes of Roche, Celgene, Bristol-Myers, Johnson & Johnson, Pfizer, AstraZeneca and

Merck, etc.) would then likely ensue. Interest could come from sector players seeking to refresh or extend patent

protection of generic and existing products, or otherwise permit introduction of more modern, potent therapeutics

that have otherwise been hindered by their extreme toxicity. Alongside revenues generated from its own in-house

developments, Avacta shareholders would stand to collect generous upfront fees, milestone payments and/or

royalties (estimated by TPI to be in the range of 5% to 15%) over the products’ lifetime.

The scale of the opportunity being presented is positively breat Cancer drug sales worldwide are already

way ahead of all other therapeutic classes and, with increasing incidence amongst aging populations, this lead is

expected to widen in coming years.

According to data analytics group Statistica, oncology drug sales reached US$176 billion in 2021, more than doubhtaking.

This dog and jam tomorrow cannot come soon enough for cancer patients who are in pain and suffering .Demonstration of safety and reduced toxicity in P2 trials is sufficient .This is why I cannot understand why a P3 trial is required as I thought AVA6000 is a drug delivery system but AVA 6000 +dox is being categorised as a novel drug (IND) over standard dox Is AS going ballistic and going to P3 trials testing AVA6000 + other similar cancer drugs to improve and broaden the application of treatments using AVA6000 ?

We were given to understand that AVA6000 was a drug delivery system and proven safe and would not require the rigours of P3 trial .Why now ? Is AVA 6000 + dox been treated as a novo drug and is replacing standard dox it certainly appears to be now for some reason

Https://www.offshore-energy.biz/lhyfe-looking-to-build-20-mw-green-hydrogen-plant-in-uk/

Why are the UK gov supporting French kit I thought Brexit would give us transformational opportunities

Rant over !